Viscosupplementation Market Analysis

Viscosupplementation Market Analysis

To get key market trends

  Download Free Sample

The viscosupplementation market from the single injection segment reached around USD 1.4 billion in 2022 and could witness significant growth through 2032 owing to the growing interest in the concept of single injection viscosupplementation. Treatment with a single injection of viscosupplementation involves administering a higher dose of hyaluronic acid in a single injection session which is convenient for the patients. Additionally, several benefits associated with the use of a single injection, such as pain relief, improved joint function, and minimal side effects, have contributed to its growing adoption rate.

The non-avian segment held a dominant share of the viscosupplementation market with revenue of around USD 2.7 billion in 2022. Non-avian sources such as bacterial fermentation or bio-fermentation using GMOs are used to produce hyaluronic acid for medical and therapeutic purposes. Non-avian hyaluronic acid is typically well-tolerated, with few side effects, making it a safer option for controlling joint discomfort, especially when compared to some drugs or invasive surgical treatments, contributing to its growing popularity.

The viscosupplementation market from the hospitals segment garnered over USD 2.2 billion in revenue in 2022. Increasing patient inclination toward treatment that provide improved outcomes has favored segment growth. The increasing patient inflow with orthopedic problems and the availability of trained specialists drive the need for high-quality hyaluronic acid injections at hospitals. Furthermore, these facilities continuously monitor patients after treatments, design workouts to recover strength, work closely with patients, and offer physical therapies. All of this contributes to the rising preference for well-equipped facilities, thereby augmenting segment gains.

North America viscosupplementation market is anticipated to reach around USD 3.4 billion by 2032. This high revenue share is attributed to the rising prevalence of arthritis and other bone-related disorders and the increased acceptance of new products across the region. Furthermore, the rising incidences of orthopedic disorders in the senior population, increasing number of traffic accidents and sports injuries, ongoing treatment innovations, and rising product demand are some of the factors propelling the regional market expansion.